Global Hematological Cancers Market Insights, Forecast to 2025

Table of Contents

1 Study Coverage

• 1.1 Hematological Cancers Product
• 1.2 Market Segments
• 1.3 Key Manufacturers Covered
• 1.4 Market by Type
  • 1.4.1 Global Hematological Cancers Market Size Growth Rate by Product
  • 1.4.2 Pharmacological Therapies
  • 1.4.3 Stem Cell Transplantation
  • 1.4.4 Surgery and Radiation Therapy
  • 1.4.5 Anemia Treatment
  • 1.4.6 Thrombosis Treatment
  • 1.4.7 Neutopenia Treatment
  • 1.4.8 Symptomatic treatment
• 1.5 Market by End User
  • 1.5.1 Global Hematological Cancers Market Size Growth Rate by End User
  • 1.5.2 Epidemiology
  • 1.5.3 Pathophysiology of Leukemic Stem Cells
  • 1.5.4 Kidney Diseases
  • 1.5.5 Genetic Diseases
  • 1.5.6 Other Diseases
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global Hematological Cancers Market Size
  • 2.1.1 Global Hematological Cancers Revenue 2014-2025
  • 2.1.2 Global Hematological Cancers Sales 2014-2025
• 2.2 Hematological Cancers Growth Rate by Regions
  • 2.2.1 Global Hematological Cancers Sales by Regions
  • 2.2.2 Global Hematological Cancers Revenue by Regions

3 Breakdown Data by Manufacturers

• 3.1 Hematological Cancers Sales by Manufacturers
  • 3.1.1 Hematological Cancers Sales by Manufacturers
  • 3.1.2 Hematological Cancers Sales Market Share by Manufacturers
  • 3.1.3 Global Hematological Cancers Market Concentration Ratio (CR5 and HHI)
• 3.2 Hematological Cancers Revenue by Manufacturers
  • 3.2.1 Hematological Cancers Revenue by Manufacturers (2014-2019)
  • 3.2.2 Hematological Cancers Revenue Share by Manufacturers (2014-2019)
• 3.3 Hematological Cancers Price by Manufacturers
• 3.4 Hematological Cancers Manufacturing Base Distribution, Product Types
  • 3.4.1 Hematological Cancers Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Hematological Cancers Product Type
  • 3.4.3 Date of International Manufacturers Enter into Hematological Cancers Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product

• 4.1 Global Hematological Cancers Sales by Product
• 4.2 Global Hematological Cancers Revenue by Product
• 4.3 Hematological Cancers Price by Product

5 Breakdown Data by End User

• 5.1 Overview
• 5.2 Global Hematological Cancers Breakdown Data by End User

6 North America

• 6.1 North America Hematological Cancers by Countries
  • 6.1.1 North America Hematological Cancers Sales by Countries
  • 6.1.2 North America Hematological Cancers Revenue by Countries
  • 6.1.3 United States
  • 6.1.4 Canada
  • 6.1.5 Mexico
• 6.2 North America Hematological Cancers by Product
• 6.3 North America Hematological Cancers by End User

7 Europe

• 7.1 Europe Hematological Cancers by Countries
  • 7.1.1 Europe Hematological Cancers Sales by Countries
  • 7.1.2 Europe Hematological Cancers Revenue by Countries
  • 7.1.3 Germany
  • 7.1.4 France
  • 7.1.5 UK
  • 7.1.6 Italy
  • 7.1.7 Russia
• 7.2 Europe Hematological Cancers by Product
• 7.3 Europe Hematological Cancers by End User

8 Asia Pacific

• 8.1 Asia Pacific Hematological Cancers by Countries
  • 8.1.1 Asia Pacific Hematological Cancers Sales by Countries
  • 8.1.2 Asia Pacific Hematological Cancers Revenue by Countries
  • 8.1.3 China
  • 8.1.4 Japan
  • 8.1.5 Korea
  • 8.1.6 India
  • 8.1.7 Australia
  • 8.1.8 Indonesia
  • 8.1.9 Malaysia
  • 8.1.10 Philippines
  • 8.1.11 Thailand
  • 8.1.12 Vietnam
  • 8.1.13 Singapore
• 8.2 Asia Pacific Hematological Cancers by Product
• 8.3 Asia Pacific Hematological Cancers by End User

9 Central & South America

• 9.1 Central & South America Hematological Cancers by Countries
  • 9.1.1 Central & South America Hematological Cancers Sales by Countries
  • 9.1.2 Central & South America Hematological Cancers Revenue by Countries
  • 9.1.3 Brazil
• 9.2 Central & South America Hematological Cancers by Product
• 9.3 Central & South America Hematological Cancers by End User

10 Middle East and Africa

• 10.1 Middle East and Africa Hematological Cancers by Countries
  • 10.1.1 Middle East and Africa Hematological Cancers Sales by Countries
  • 10.1.2 Middle East and Africa Hematological Cancers Revenue by Countries
  • 10.1.3 GCC Countries
  • 10.1.4 Turkey
  • 10.1.5 Egypt
  • 10.1.6 South Africa
• 10.2 Middle East and Africa Hematological Cancers by Product
• 10.3 Middle East and Africa Hematological Cancers by End User

11 Company Profiles

• 11.1 Karyopharm Therapeutics
  • 11.1.1 Karyopharm Therapeutics Company Details
  • 11.1.2 Company Business Overview
  • 11.1.3 Karyopharm Therapeutics Hematological Cancers Sales, Revenue and Gross Margin (2014-2019)
  • 11.1.4 Karyopharm Therapeutics Hematological Cancers Products Offered
  • 11.1.5 Karyopharm Therapeutics Recent Development
• 11.2 Johnson & Johnson
  • 11.2.1 Johnson & Johnson Company Details
  • 11.2.2 Company Business Overview
  • 11.2.3 Johnson & Johnson Hematological Cancers Sales, Revenue and Gross Margin (2014-2019)
  • 11.2.4 Johnson & Johnson Hematological Cancers Products Offered
  • 11.2.5 Johnson & Johnson Recent Development
• 11.3 Roche Diagnostics A/S
  • 11.3.1 Roche Diagnostics A/S Company Details
  • 11.3.2 Company Business Overview
  • 11.3.3 Roche Diagnostics A/S Hematological Cancers Sales, Revenue and Gross Margin (2014-2019)
  • 11.3.4 Roche Diagnostics A/S Hematological Cancers Products Offered
  • 11.3.5 Roche Diagnostics A/S Recent Development
• 11.4 AbbVie
  • 11.4.1 AbbVie Company Details
  • 11.4.2 Company Business Overview
  • 11.4.3 AbbVie Hematological Cancers Sales, Revenue and Gross Margin (2014-2019)
  • 11.4.4 AbbVie Hematological Cancers Products Offered
  • 11.4.5 AbbVie Recent Development
• 11.5 Novartis
  • 11.5.1 Novartis Company Details
  • 11.5.2 Company Business Overview
  • 11.5.3 Novartis Hematological Cancers Sales, Revenue and Gross Margin (2014-2019)
  • 11.5.4 Novartis Hematological Cancers Products Offered
  • 11.5.5 Novartis Recent Development
• 11.6 Kite Pharma
  • 11.6.1 Kite Pharma Company Details
  • 11.6.2 Company Business Overview
  • 11.6.3 Kite Pharma Hematological Cancers Sales, Revenue and Gross Margin (2014-2019)
  • 11.6.4 Kite Pharma Hematological Cancers Products Offered
  • 11.6.5 Kite Pharma Recent Development
• 11.7 Celgene Corporation
  • 11.7.1 Celgene Corporation Company Details
  • 11.7.2 Company Business Overview
  • 11.7.3 Celgene Corporation Hematological Cancers Sales, Revenue and Gross Margin (2014-2019)
  • 11.7.4 Celgene Corporation Hematological Cancers Products Offered
  • 11.7.5 Celgene Corporation Recent Development
• 11.8 Abbott Laboratories
  • 11.8.1 Abbott Laboratories Company Details
  • 11.8.2 Company Business Overview
  • 11.8.3 Abbott Laboratories Hematological Cancers Sales, Revenue and Gross Margin (2014-2019)
  • 11.8.4 Abbott Laboratories Hematological Cancers Products Offered
  • 11.8.5 Abbott Laboratories Recent Development
• 11.9 Beckman Coulter
  • 11.9.1 Beckman Coulter Company Details
  • 11.9.2 Company Business Overview
  • 11.9.3 Beckman Coulter Hematological Cancers Sales, Revenue and Gross Margin (2014-2019)
  • 11.9.4 Beckman Coulter Hematological Cancers Products Offered
  • 11.9.5 Beckman Coulter Recent Development
• 11.10 HemoCue AB
  • 11.10.1 HemoCue AB Company Details
  • 11.10.2 Company Business Overview
  • 11.10.3 HemoCue AB Hematological Cancers Sales, Revenue and Gross Margin (2014-2019)
  • 11.10.4 HemoCue AB Hematological Cancers Products Offered
  • 11.10.5 HemoCue AB Recent Development
• 11.11 C. R. Bard
• 11.12 Siemens AG
• 11.13 Sysmex
• 11.14 Mindray Medical International Limited
• 11.15 Bio-Rad Laboratories
• 11.16 The Medicine Company
• 11.17 Pharmacyclics
• 11.18 Horiba
• 11.19 DiagnoCure Inc.
• 11.20 Astellas Pharma US

12 Future Forecast

• 12.1 Hematological Cancers Market Forecast by Regions
  • 12.1.1 Global Hematological Cancers Sales Forecast by Regions 2019-2025
  • 12.1.2 Global Hematological Cancers Revenue Forecast by Regions 2019-2025
• 12.2 Hematological Cancers Market Forecast by Product
  • 12.2.1 Global Hematological Cancers Sales Forecast by Product 2019-2025
  • 12.2.2 Global Hematological Cancers Revenue Forecast by Product 2019-2025
• 12.3 Hematological Cancers Market Forecast by End User
• 12.4 North America Hematological Cancers Forecast
• 12.5 Europe Hematological Cancers Forecast
• 12.6 Asia Pacific Hematological Cancers Forecast
• 12.7 Central & South America Hematological Cancers Forecast
• 12.8 Middle East and Africa Hematological Cancers Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Hematological Cancers Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details